Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | NCK1 | P16333 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2701987 | 0.91 | CYP1A2 (0.54) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| SCHEMBL2701718 | 0.91 | CYP1A2 (0.54) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| SCHEMBL645286 | 0.91 | CYP1A2 (0.56) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| SCHEMBL18317243 | 0.81 | CYP1A2 (0.46) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| Water SCHEMBL27539226 | 0.80 | CYP1A2 (0.93) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| SCHEMBL18317357 | 0.79 | CYP1A2 (0.44) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| SCHEMBL4010083 | 0.79 | SNCA (0.51) | CYP1A2CYP2A6ALDH1A1LMNAGAA | |
| SCHEMBL18317633 | 0.78 | CYP1A2 (0.45) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| SCHEMBL29389285 | 0.77 | CYP1A2 (1.00) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 | |
| SCHEMBL308248 | 0.77 | CYP1A2 (1.00) | CYP1A2CYP2A6TDP1ALDH1A1NCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 628 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | claimed |
| EP-2778160-B1 | CYCLIC AZINE COMPOUND HAVING NITROGEN-CONTAINING FUSED AROMATIC GROUP, METHOD FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME AS CONSTITUENT COMPONENT | TOSOH CORP (JP) | 2018-01-10 | — | — | EP | claimed |
| CN-106854218-A | A kind of silicon anthracene derivative and preparation method thereof and organic luminescent device | 上海升翕光电科技有限公司 | 2017-06-16 | — | — | CN | claimed |
| EP-2892892-B1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-31 | — | — | EP | claimed |
| CN-106632446-A | Benzosilole derivatives, preparation method thereof and organic light emitting device | 上海升翕光电科技有限公司 | 2017-05-10 | — | — | CN | claimed |
| US-9252368-B2 | Cyclic azine compound having nitrogen-containing condensed aromatic group, method for producing same, and organic electroluminescent device comprising same as constituent component | TOSOH CORPORATION (JP) | 2016-02-02 | — | — | US | claimed |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-07 | — | — | US | claimed |
| EP-2892892-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR!THE TREATMENT OF CANCER | Janssen Pharmaceutica N.V. (BE) | 2015-07-15 | — | — | EP | claimed |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, NV (BE) | 2015-04-09 | — | — | US | claimed |
| US-20140330013-A1 | CYCLIC AZINE COMPOUND HAVING NITROGEN-CONTAINING FUSED AROMATIC GROUP, METHOD FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT | TOSOH CORPORATION (JP) | 2014-11-06 | — | — | US | claimed |
| EP-0231497-A1 | Silicone resist materials containing polysiloxanes | KABUSHIKI KAISHA TOSHIBA (JP) | 1987-08-12 | — | — | EP | claimed |
| US-4125619-A | ANTITHROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES, LTD. (JP) | 1978-11-14 | — | — | US | claimed |
| US-4104392-A | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1978-08-01 | — | — | US | claimed |
| US-4096255-A | ANTICOAGULANTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-06-20 | — | — | US | claimed |
| US-4073916-A | THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-02-14 | — | — | US | claimed |
| US-4073914-A | THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-02-14 | — | — | US | claimed |
| US-4072744-A | SUPPRESSION OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-02-07 | — | — | US | claimed |
| US-4070457-A | ANTITHROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1978-01-24 | — | — | US | claimed |
| US-4049645-A | ANTITHROMBOTIC AGENTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1977-09-20 | — | — | US | claimed |
| US-4036955-A | TREATMENT OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1977-07-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | CYP1A2 439/4885CYP2A6 1519/4885TDP1 2302/4885 |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | FASN, PLIN1, FABP1 | CYP1A2 439/4885CYP2A6 1519/4885TDP1 2302/4885 |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | CYP1A2 439/4885CYP2A6 1519/4885TDP1 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.